BDSI · Biodelivery Sciences International Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $41.09M | $41.44M | $41.02M | - | $39.44M | $36.58M | $38.28M | - | $30.31M |
| Cost of Revenue | - | $6.37M | $4.28M | $5.82M | - | $5.38M | $5.43M | $5.56M | - | $5.35M |
| Gross Profit | - | $34.73M | $37.16M | $35.20M | - | $34.07M | $31.15M | $32.72M | - | $24.96M |
| R&D | - | - | - | - | - | - | - | - | - | $0 |
| SG&A | - | $25.47M | $25.78M | $27.76M | - | $22.46M | $28.21M | $26.74M | - | $23.36M |
| Total Operating Expenses | - | $25.47M | $25.78M | $27.76M | - | $22.46M | $28.21M | $26.74M | - | $23.36M |
| D&A | - | $40.0K | $30.0K | $19.0K | - | $20.0K | $400.0K | $21.0K | - | $80.0K |
| Operating Income | - | $9.26M | $11.38M | $7.44M | - | $11.61M | $2.94M | $5.98M | - | $1.60M |
| Interest Expense | - | $1.98M | $2.00M | $1.98M | - | $2.01M | $1.69M | $1.29M | - | $1.23M |
| Income Tax | - | $606.0K | $312.0K | $222.0K | - | $211.0K | $86.0K | ($278.0K) | - | $5.0K |
| Net Income | - | $6.67M | $10.20M | $5.24M | - | $9.38M | $1.17M | $4.97M | - | $354.0K |
| EPS - Basic | - | $0.07 | $0.09 | $0.05 | - | $0.09 | $0.01 | $0.05 | - | $0.00 |
| EPS - Diluted | - | $0.07 | $0.09 | $0.05 | - | $0.09 | $0.01 | $0.05 | - | $0.00 |
Balance Sheet
| Line item | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $114.30M | $100.71M | $119.85M | $116.44M | $111.58M | $100.18M | $91.01M | $70.61M | $63.89M | $55.86M |
| Accounts Receivable | $56.87M | $57.57M | $52.87M | $48.29M | $48.15M | $43.83M | $48.13M | $45.11M | $38.79M | $33.42M |
| Inventory | $23.71M | $23.07M | $18.66M | $16.97M | $17.44M | $18.89M | $17.77M | $15.00M | $11.31M | $10.77M |
| Accounts Payable | $8.11M | $7.03M | $4.07M | $5.31M | $4.21M | $8.24M | $13.29M | $17.70M | $11.70M | $2.17M |
| Current Assets | $202.06M | $188.26M | $196.06M | $186.15M | $182.38M | $168.65M | $159.01M | $133.33M | $117.76M | $104.92M |
| Total Assets | $324.60M | $256.07M | $250.33M | $242.13M | $239.89M | $227.96M | $220.07M | $196.62M | $182.91M | $173.61M |
| Current Liabilities | $82.38M | $77.66M | $63.91M | $54.58M | $52.99M | $53.41M | $56.65M | $60.93M | $53.99M | $46.55M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $136.77M | $133.29M | $136.41M | $133.28M | $131.66M | $132.07M | $135.30M | $120.03M | $113.14M | $105.71M |
| Stockholders' Equity | $187.82M | $122.78M | $113.92M | $108.85M | $108.23M | $95.89M | $84.77M | $76.59M | $69.76M | $67.89M |
| Retained Earnings | ($256.02M) | ($319.91M) | ($326.58M) | ($335.64M) | ($340.88M) | ($351.08M) | ($360.46M) | ($361.63M) | ($366.59M) | ($365.90M) |
Cash Flow
| Line item | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | $11.10M | - | - | - | $6.39M | - | - |
| Investing Cash Flow | - | - | - | ($296.0K) | - | - | - | $0 | - | - |
| Financing Cash Flow | - | - | - | ($5.95M) | - | - | - | $338.0K | - | - |
| CapEx | - | - | - | $296.0K | - | - | - | $0 | - | - |
| Free Cash Flow | - | - | - | $10.80M | - | - | - | $6.39M | - | - |
Ratios
| Metric | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 | Q3 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 84.5% | 89.7% | 85.8% | - | 86.4% | 85.1% | 85.5% | - | 82.3% |
| Operating margin | - | 22.5% | 27.5% | 18.1% | - | 29.4% | 8.0% | 15.6% | - | 5.3% |
| EBITDA margin | - | 22.6% | 27.5% | 18.2% | - | 29.5% | 9.1% | 15.7% | - | 5.5% |
| Net margin | - | 16.2% | 24.6% | 12.8% | - | 23.8% | 3.2% | 13.0% | - | 1.2% |
| Free cash flow margin | - | - | - | 26.3% | - | - | - | 16.7% | - | - |
| FCF / Net income | - | - | - | 2.06 | - | - | - | 1.29 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | 0.0% |
| SG&A / Revenue | - | 62.0% | 62.2% | 67.7% | - | 56.9% | 77.1% | 69.8% | - | 77.1% |
| Effective tax rate | - | 8.3% | 3.0% | 4.1% | - | 2.2% | 6.9% | -5.9% | - | 1.4% |
| Return on assets | - | 2.6% | 4.1% | 2.2% | - | 4.1% | 0.5% | 2.5% | - | 0.2% |
| Return on equity | - | 5.4% | 9.0% | 4.8% | - | 9.8% | 1.4% | 6.5% | - | 0.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.45 | 2.42 | 3.07 | 3.41 | 3.44 | 3.16 | 2.81 | 2.19 | 2.18 | 2.25 |
| Quick ratio | 2.17 | 2.13 | 2.78 | 3.10 | 3.11 | 2.80 | 2.49 | 1.94 | 1.97 | 2.02 |
| Cash ratio | 1.39 | 1.30 | 1.88 | 2.13 | 2.11 | 1.88 | 1.61 | 1.16 | 1.18 | 1.20 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | 4.7x | 5.7x | 3.8x | - | 5.8x | 1.7x | 4.6x | - | 1.3x |
| Equity multiplier | 1.73 | 2.09 | 2.20 | 2.22 | 2.22 | 2.38 | 2.60 | 2.57 | 2.62 | 2.56 |
| Liabilities / Assets | 0.42 | 0.52 | 0.54 | 0.55 | 0.55 | 0.58 | 0.61 | 0.61 | 0.62 | 0.61 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.16 | 0.17 | 0.17 | - | 0.17 | 0.17 | 0.19 | - | 0.17 |
| Inventory turnover | - | 0.28 | 0.23 | 0.34 | - | 0.28 | 0.31 | 0.37 | - | 0.50 |
| Days sales outstanding | - | 511d | 466d | 430d | - | 406d | 480d | 430d | - | 403d |
| Days inventory outstanding | - | 1323d | 1590d | 1064d | - | 1282d | 1194d | 985d | - | 735d |
| Days payable outstanding | - | 403d | 347d | 333d | - | 560d | 892d | 1162d | - | 148d |
| Cash conversion cycle | - | 1431d | 1708d | 1161d | - | 1128d | 781d | 253d | - | 989d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 4.2% | 13.3% | 7.2% | - | 30.1% | 23.3% | 93.6% | - | 169.3% |
| Revenue CAGR (3y) | - | 54.0% | 68.0% | 53.8% | - | 51.9% | 61.1% | 9.1% | - | 104.0% |
| Revenue CAGR (5y) | - | 63.0% | 52.6% | 68.3% | - | 99.9% | 84.0% | 24.0% | - | 75.5% |
| Gross profit growth (YoY) | - | 1.9% | 19.3% | 7.6% | - | 36.5% | 25.8% | 100.1% | - | 233.9% |
| Operating income growth (YoY) | - | -20.2% | 287.5% | 24.3% | - | 627.2% | 4.9% | - | - | - |
| Net income growth (YoY) | - | -28.9% | 775.2% | 5.5% | - | 2550.8% | - | - | - | - |
| EPS growth (YoY) | - | -22.2% | 800.0% | 0.0% | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | -61.4% | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | 69.1% | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | 68.7% | - | - |
| Book value growth (YoY) | 73.5% | 28.0% | 34.4% | 42.1% | 55.1% | 41.2% | 28.1% | 178.3% | 134.6% | 90.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$331.30M totalProduct$164.60M · 49.7%
Belbuca$148.19M · 44.7%
Symproic$16.41M · 5.0%
Royalty$2.10M · 0.6%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BIODELIVERY SCIENCES INTERNATIONAL INC against the 5 most active filers in the same SIC group.